Functional assessment and partial characterization of [3H](+)-pentazocine binding sites on cells of the immune system.
The existence of sigma receptors on lymphocytes and thymocytes was characterized using [3H](+)-pentazocine. [3H](+)-Pentazocine specifically labels high affinity sigma-type binding sites on T- and B-enriched lymphocyte membranes. The binding is saturable with T lymphocyte sites having a KD value of 401 +/- 85 nM and B lymphocyte sites having a KD value of 302 +/- 46 nM. Likewise, saturable high (KD1 277 +/- 92 nM) and low (KD2 2.5 +/- 1.2 microM) affinity sites for [3H](+)-pentazocine are found on thymocytes as well. In competition studies with lymphocytes, the rank order of potency for competing ligands is (+)-pentazocine = N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2- (1-pyrrolidinyl)ethylamine (BD1008) greater than 1R,2S-(+)-cis-N-(2-(3,4-dichlorophenyl)ethyl]-2- (1-pyrrolidinyl)cyclohexylamine (LR132) greater than or equal to (-)-pentazocine greater than or equal to phenazocine greater than (+/-)-trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] benzeneacetamide methanesulphonate (U-50,488H) = phencyclidine greater than haloperidol = 1,3-di- (o)-tolylguanidine. In competition studies with thymocytes, the rank order of potency for competing ligands is (+)-pentazocine = BD1008 greater than or equal to phenazocine greater than haloperidol greater than 1,3-di-(o)-tolylguanidine greater than phencyclidine greater than (-)-pentazocine. These compounds were also investigated as potential regulatory molecules in mitogen-stimulated lymphocyte proliferation assays. Of the compounds tested, phencyclidine, 1,3-di-(o)-tolylguanidine, haloperidol, and (+)-pentazocine suppress concanavalin A-induced proliferation at high (10(-5) M) concentrations while (-)-pentazocine is inactive. When pokeweed mitogen or lipopolysaccharide are used, these compounds enhance or suppress lymphocyte proliferation depending on the mitogen and concentration of ligand. These results indicate a stereoselective receptor for (+)-pentazocine which is coupled to biological processes of lymphocytes.
Carr
D J
DJ
Department of Physiology and Biophysics, University of Alabama, Birmingham 35294-0005.
De Costa
B R
BR
Radesca
L
L
Blalock
J E
JE
D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D003208:Concanavalin A / Q000494:pharmacology; D005260:Female; D007107:Immune System / Q000166:cytology / Q000378:metabolism*; D007376:Interleukin-2 / Q000037:antagonists & inhibitors; D015847:Interleukin-4 / Q000037:antagonists & inhibitors; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D010423:Pentazocine / Q000378:metabolism*; D013154:Spleen / Q000166:cytology; D013237:Stereoisomerism; D013950:Thymus Gland / Q000166:cytology / Q000378:metabolism; D014316:Tritium
D007376:Interleukin-2; D014316:Tritium; D003208:Concanavalin A; D015847:Interleukin-4; D010423:Pentazocine